India’s Biotech Surge

India’s Biotech Surge: Aspirations, Infrastructure Gaps, and Institutional Complexity

From a mere 500 startups in 2018 to over 10,000 in 2025, India’s biotechnology ecosystem has seen explosive growth. With bioeconomy now contributing 4.25% to GDP and poised for a $300 billion target by 2030, the scale of ambition is undeniable. But ambition alone is never enough—it must contend with fractured execution, regulatory bottlenecks, and uneven infrastructure.

Structural Underpinnings of India’s Biotechnology Sector

India’s bioeconomy is administered across overlapping institutional frameworks, most visibly under the Department of Biotechnology (DBT), which spearheads initiatives such as the BioE3 Policy (2024) and programmes like the Bioenergy Ethanol Blending Scheme. The Biotechnology Industry Research Assistance Council (BIRAC), established in 2012, plays a crucial role by funding startups and enabling infrastructure at 95 bio-incubation centres. On paper, the structure is robust—DBT focuses on policy, BIRAC emphasizes implementation, and sector categories like biopharma, bio-agriculture, bio IT, and bio services provide clear specializations.

However, gaps remain. Despite hosting over 70 incubators, India lacks end-to-end facilities for biopharma startups—critical stages like purification systems, regulatory compliance support, and pilot-scale manufacturing require entrepreneurs to liaise across multiple cities, inflating costs. Likewise, the sector’s focus on bio-agriculture under initiatives like Biotech-KISAN has delivered innovations such as genome-edited rice (DEP1-edited MTU-1010) and IndRA SNP arrays, but access beyond pilot-scale demonstration often falters.

What the Numbers Reveal—and Obscure

The headline growth of India’s bioeconomy—16-fold increase between 2014 and 2024—is as much about policy framing as genuine innovation. Ethanol blending rising from 1.53% in 2014 to 15% in 2024 is commendable, and targets for 20% blending by 2025 could make India a regional leader in bioenergy. However, regulatory complexity threatens momentum. Outdated frameworks governing clinical trials, patents for biologics, and product approvals remain ill-suited for modern biotech demands like AI integration in genomics.

Take the National Biopharma Mission, which aims to drive vaccines, biosimilars, and diagnostics innovation. While its ambition to merge academia and industry collaboration is laudable, implementation is marred by fragmented policy ecosystems. For example, separate environmental clearances and production licensing for biotech parks add layers of bureaucracy—deterring foreign investors who compare their ease of operations elsewhere. The gap between promise and execution compromises India's positioning against global leaders.

Fragmentation and Weak International Comparisons: The US Model

India often cites biopharma potential, yet the country still lags behind biotech-heavy destinations like the United States. Take the case of biologics manufacturing: In the US, the Advanced Biopharmaceutical Manufacturing Consortium enables streamlined tax credits and single-window clearance mechanisms for research parks. In contrast, India’s ecosystem requires startups to engage with disparate bodies—BIRAC, DBT, state-level regulatory agencies—leading to duplications.

The US also incentivizes early-stage research through extensive seed grants under NIH programs, linking universities directly to commercialization pipelines. Indian efforts, notably BIRAC’s bio-incubation strategy, are commendable but lack coverage for transition from prototype to full-scale production. India's fragmented logistical chain contrasts starkly with the centralized research hubs in the US, which foster cohesion between private-sector innovation and academic expertise.

Policy Missteps and Structural Tensions

Despite its framing as a global benchmark initiative, the BioE3 Policy masks significant weaknesses. Regulatory inefficiency remains glaring—whether in approvals for genome-edited crops or fast-track vaccine clearances. While genome-edited rice varieties (like DEP1-edited MTU-1010) or drought-resistant chickpeas (SAATVIK) represent breakthroughs, commercial success is hindered by bureaucratic inertia. State governments and central bodies often operate at cross-purposes, with divergent priorities over environmental risks or land use.

The ethanol blending programme’s projected 20% target by 2025 also highlights Centre-state friction. States with diversified agro-industries might prioritize rice or sugar cane usage differently than ethanol-intensive states. Without fiscal incentives to mitigate structural variation, ethanol blending risks becoming another disjointed resource allocation exercise—not the transformative bioenergy pathway envisioned.

Forward Path: Metrics for Success and Areas of Uncertainty

What could success look like for India’s biotech ambitions? Three metrics stand out. First, creation of a centralized regulatory body capable of AI-assisted patent tracking and harmonized frameworks for biologics approvals. Second, scaling bio-incubation centres to integrate end-to-end facilities, ensuring continuity from innovation to market launches. Finally, the Centre must incentivize state-level collaboration—particularly for programmes like ethanol blending where agro-economic variables are intensely region-specific.

But uncertainties remain. India’s bold $300-billion bioeconomy target by 2030 assumes linear growth—a risky bet considering supply-chain inefficiencies, talent shortages, and shifting global attention to net-zero sustainability efforts. Achieving scale while maintaining ecological balance will remain a tightrope walk.

Practice Questions for UPSC

Prelims Practice Questions

Frequently Asked Questions